| 2026-08-06 | Press release | Viatris Reports Second-Quarter 2026 Financial Results |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-06 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-04 | Press release | Viatris Announces Quarterly Dividend |
| 2026-07-29 | Press release | Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch |
| 2026-07-01 | Press release | Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 |
| 2026-07-01 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-29 | Press release | Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin |
| 2026-06-18 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-15 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-18 | Press release | U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pa |
| 2026-05-15 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-07 | Press release | Viatris Reports First-Quarter 2026 Financial Results |
| 2026-05-07 | Press release | Viatris to Present at the Bank of America Securities 2026 Healthcare Conference |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-05 | Press release | Viatris Announces Quarterly Dividend |
| 2026-05-04 | Press release | Viatris Announces Chief Financial Officer Transition |
| 2026-05-04 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-02 | Proxy | Definitive proxy statement |
| 2026-03-02 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-26 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-26 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-03 | 8-K | Form 8-K, Item 5.02 |
| 2025-12-08 | 8-K | Form 8-K, Item 7.01 |
| 2025-12-05 | 8-K | Form 8-K/A, Item 5.02 |
| 2025-12-05 | 8-K | Form 8-K, Item 5.07 |
| 2025-11-06 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-06 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-24 | 8-K | Form 8-K, Item 5.03 |
| 2025-10-24 | Proxy | Definitive proxy statement |
| 2025-08-07 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-07 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-08-05 | 8-K | Form 8-K, Item 5.02 |
| 2025-05-08 | 8-K | Form 8-K, Item 2.02 results |
| 2025-05-08 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2025-05-05 | 8-K | Form 8-K, Item 5.02 |
| 2025-04-30 | 10-K | Annual report on Form 10-K/A, FY24 |
| 2025-02-27 | 8-K | Form 8-K, Item 2.02 results |